5 year outcomes of SOC Axicabtagene Ciloleucel

Graham Collins, Associate Professor of Haematology and lymphoma specialist at Oxford Cancer and Haematology centre, shared on X:

“5 year outcomes SOC Axi-Cel (Standard-of-Care Axicabtagene Ciloleucel): US real world data, Michael Jain et al.

• All 3rd+ line, 298 leucopheresed patients
• 5 year PFS/OS 29%/40%
• 5 year NRM (Non-Relapse Mortality) 16% (Infections/ 2nd malignancies dominant)
• NRM higher in > 60 year
Worrying NRM. Could this be lower when used 2nd line (less prior treatment)?”

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Authors: Michael D. Jain, Jay Y. Spiegel, Loretta J. Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin, Lazaros Lekakis, Patrick Reagan, Olalekan Oluwole, Joseph McGuirk, Abhinav Deol, Kathleen A. Dorritie, Alison R. Sehgal, Andre Goy, Brian T. Hill, Charalambos Andreadis, Javier Munoz, Matthew Ulrickson, Jason Westin, Julio C. Chavez, Dilan Patel, Miriam T. Jacobs, Radhika Bansal, N. Nora Bennani, Vivek G. Patel, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke, Matthew Lunning and Saurabh Dahiya.

Source: Graham Collins/X